HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SHC
Sotera Health Company
SHC's fundamentals are strong and it looks cheap: trading at 27x earnings, less than half its usual 61x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Weak |
SHC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $16.30 | — |
| Current | 27x | $16.30 | — |
| Cheap | 38x | $23.00 | +41% |
| Fair | 61x | $36.40 | +123% |
| Expensive | 173x | $104 | +538% |
Historical ranges are pointers, not guarantees.
SHC's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
SHC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.04 | +73% |
| Q3 2026 | $0.60 | +200% |
| Q2 2026 | $0.57 | +533% |
| Q1 2026 | $0.41 | +356% |
| Q4 2025 | $0.27 | +69% |
| Q3 2025 | $0.20 | -20% |
| Q2 2025 | $0.09 | -36% |
| Q1 2025 | $0.09 | -53% |
| Q4 2024 | $0.16 | -11% |
SHC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SHC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $324.9M | +4.4% |
| Q2 2026 | $321.4M | +9.2% |
| Q1 2026 | $280M | +10% |
| Q4 2025 | $303.4M | +4.6% |
| Q3 2025 | $311.3M | +9.1% |
| Q2 2025 | $294.3M | +6.4% |
| Q1 2025 | $254.5M | +2.6% |
| Q4 2024 | $290.2M | -6.5% |
SHC's revenue has grown year over year for seven quarters in a row: $325M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | +2.3 points |
| Q2 2026 | 24% | +18 points |
| Q1 2026 | 15% | +21 points |
| Q4 2025 | 23% | -6.8 points |
| Q3 2025 | 23% | -4.8 points |
| Q2 2025 | 6.4% | -21 points |
| Q1 2025 | -5.8% | -27 points |
| Q4 2024 | 30% | -3.5 points |
SHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SHC on cash flow, with more consistent year-over-year improvement.
SHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57.7M | +65% |
| Q2 2026 | $42M | +61% |
| Q1 2026 | -$16.7M | -147% |
| Q4 2025 | $52.4M | +$62.6M |
| Q3 2025 | $35M | -43% |
| Q2 2025 | $26.2M | +35% |
| Q1 2025 | $35.6M | +$60.8M |
| Q4 2024 | -$10.2M | -121% |
SHC generated $135M in free cash flow over the past year, up 56% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +2.9% | +8.1M shares |
| 5 years | +3.5% | +9.7M shares |
| Available history | +3.7% | +10.4M shares |
SHC has 289M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 4.6x | High |
| Q1 2026 | 5.5x | High |
| Q4 2025 | 6.3x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 4.9x | High |
| Q4 2024 | 4.2x | High |
SHC's net debt is about 4.3 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 20.9 | Neutral |
SHC's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SHC PE vs Healthcare Sector
| Metric | SHC | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 5.1% above |
| PE % | 8 | 34 | 26 pts below |
SHC is trading at 27x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.6 | 7.5% below |
| 20 week MA | $18.2 | 10% below |
| 50 week MA | $17.1 | 4.4% below |
| 100 week MA | $15.3 | 6.7% above |
| 200 week MA | $15.1 | 7.9% above |
SHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.1 | $26.9 | +7.3% |
| 2021 | $26.9 | $23.6 | -13% |
| 2022 | $23.6 | $7.93 | -66% |
| 2023 | $7.93 | $16.9 | +112% |
| 2024 | $16.9 | $13.5 | -20% |
| 2025 | $13.5 | $17.7 | +31% |
| 2026 YTD | $17.7 | $16.3 | -7.9% |
SHC has the edge over HIMS on returns for 2026, with the stronger performance.